German market leader within a few years

Business development

M1 has a clear growth strategy within the established business model. Since the opening of our first location in Berlin in 2012, we have continuously developed. Today, M1 is the market leader in Germany and has started the international expansion. In the coming years we will open numerous new locations in Germany and roll out the successful their model internationally. We see great potential in practically every country in Western Europe and beyond. After all, the markets for cosmetic surgery are very fragmented and prices are too high.

In addition, we see potential in other areas of aesthetic and plastic medicine and, from a medical point of view, the demand for specialization. That, we want to take advantage of.


Outlook: targets by the end of 2025

Growth targets

  • to operate approx. 75 - 100 M1 Med Beauty outpatient clinics
  • to be a leading lifestyle brand in aesthetic medicine
  • to be internationally known with our own brand for medical cosmetics

 

Latest news

| Investor News

  • Management is open to interested parties
  • Valuations in the peer group of up to 30 times the annual EBITDA
  • M1 Kliniken AG expects EBITDA of over EUR 27 million in 2024

| Investor News

By acquiring the German Nutri Care GmbH and its wholly-owned subsidiary, the Dutch online pharmacy "Direct Apotheke Venlo B.V.," M1 Kliniken AG (ISIN: DE000A0STSQ8) taps into a significant growth field and expands the value chain of its health services. Direct Apotheke Venlo B.V., based in Maasbree (NL), is one of the rapidly growing providers in the online pharmacy business for aesthetic pharmaceuticals, with current core markets in Germany and the Netherlands. In the fiscal year 2022, the company recorded double-digit million-euro revenues and continues on a growth trajectory.

| Investor News

  • Group sales increase by over 10% to EUR 236.6 million in the first nine months of the 2023 financial year (previous year: EUR 214.2 million).

  • Group EBITDA increases by over 55% from EUR 10.9 million to EUR 16.9 million.

  • The operating result (Group EBIT) increases by over 98% to EUR 12.9 million (previous year: EUR 6.5 million).

  • Beauty segment: sales increase of 28.5% to EUR 53.2 million (previous year: EUR 41.4 million) and sharp rise in the Beauty EBIT margin from 8.2% to 23.5%

| Investor News

  • 20th Location outside Germany opened in Bucharest, Romania
  • Break-even expected for foreign locations within the next 12 months
  • Subsidiary established in the USA: Market entry into the world's largest market for beauty medicine expected in 2024